IDO Targeting in Sarcoma: Biological and Clinical Implications

Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy. We recently demonstrated an increase in Kynurenine Pathway (KP) activity in the plasma of sarcoma patients treated with pembrolizumab. While the KP has already been described to favor immune escape...

Descripción completa

Detalles Bibliográficos
Autores principales: Nafia, Imane, Toulmonde, Maud, Bortolotto, Doriane, Chaibi, Assia, Bodet, Dominique, Rey, Christophe, Velasco, Valerie, Larmonier, Claire B., Cerf, Loïc, Adam, Julien, Le Loarer, François, Savina, Ariel, Bessede, Alban, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066301/
https://www.ncbi.nlm.nih.gov/pubmed/32194552
http://dx.doi.org/10.3389/fimmu.2020.00274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066301/
https://www.ncbi.nlm.nih.gov/pubmed/32194552
http://dx.doi.org/10.3389/fimmu.2020.00274

Ejemplares similares